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Use of aspirin after diagnosis of colon cancer has been associated with improved survival.
Identification of cancer subtypes that respond to aspirin treatment may help develop person-
alized treatment regimens. The aim of this study was to investigate the influence of BRAF
and KRAS mutation status on the association between aspirin use and overall survival after
colon cancer diagnosis.
Methods
A random selection of 599 patients with colon cancer were analyzed, selected from the
Eindhoven Cancer Registry, and BRAF and KRAS mutation status was determined. Data
on aspirin use (80 mg) were obtained from the PHARMO Database Network. Parametric
survival models with exponential (Poisson) distribution were used.
Results
Aspirin use after colon cancer diagnosis was associated with improved overall survival in
wild-type BRAF tumors, adjusted rate ratio (RR) of 0.60 (95% CI 0.44–0.83). In contrast,
aspirin use in BRAF mutated tumors was not associated with an improved survival (RR
1.11, 95% CI 0.57–2.16). P-value for interaction was non-significant. KRAS mutational sta-
tus did not differentiate in the association between aspirin use and survival.
Conclusion
Low-dose aspirin use after colon cancer diagnosis was associated with improved survival in
BRAF wild-type tumors only. However, the large confidence interval of the rate ratio for the
use of aspirin in patients with BRAF mutation does not rule out a possible benefit. These
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Introduction
A significant body of proof has already demonstrated that aspirin has anticancer effects in
colorectal cancer (CRC) [1–5]. Randomized controlled trials investigating the cardiovascular
benefits of aspirin have shown a significant reduction of CRC risk and mortality [1, 6, 7]. In
patients with a history of colorectal adenomas, aspirin has been proven effective in the pre-
vention of these lesions [8]. The most recent meta-analysis of observational studies by
Elwood et al. found a 25% reduction in colorectal cancer-related deaths and a 20% overall
mortality reduction [4]. Altogether, these publications have led to several ongoing random-
ized controlled trials studying the effect of aspirin on cancer mortality which are currently
being conducted globally: the Add-Aspirin trial [9], Adjuvant Aspirin for Colon Cancer
(NCT02467582), the ALASCCA trial (NCT02647099), the ASCOLT trial (NCT00565708),
and the Aspirin trial (NCT02301286).
If the survival benefits are so obvious, why not prescribe aspirin to all colorectal cancer
patients? Because of the side-effects, the use of aspirin is not without risk: common adverse
effects are upper gastrointestinal symptoms, and increased bleeding tendency which can cause
epistaxis, gastrointestinal bleeding or purpura [5]. Low-dose aspirin, indicated for secondary
cardiovascular risk management, roughly doubles the incidence of gastric bleeding. One or
two patients in every thousand are likely to have a gastric bleed each year. The bleeding risk
increases with age and in patients 80 years and older, this may even be seven per 1000 people
per year [10]. Identifying which patients may benefit from aspirin treatment may help develop
effective personalized treatment regimens, thereby reducing overtreatment and negative side
effects associated with aspirin. Several biomarkers have been suggested to be differentiating in
the association between aspirin and improved cancer survival, however results are very hetero-
geneous [5]. Despite promising data, the clinical use of any biomarker in general practice is
lacking, and currently only KRAS, BRAF and microsatellite instability are currently used in the
diagnosis and treatment of colorectal cancer [11].
Mutated BRAF and KRAS oncogenes, both members of the Mitogen Activated Protein
Kinase (MAPK) pathway, are respectively observed in approximately 10–20% and 35–42% of
the sporadic colorectal cancers [11–13]. Mutated BRAF and KRAS have been shown to influ-
ence MAPK signaling, resulting in upregulation of Prostaglandin-endoperoxide synthase 2
(PTGS2, also known as COX-2) [14]. BRAFmutations are associated with the presence of high
microsatellite instability, the molecular hallmark of Lynch syndrome [15]. Evidence from the
CAPP2 trial demonstrated that individuals with Lynch syndrome could be recommended to
consider taking daily low-dose aspirin [16]. With this link and the known crosstalk between
the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) pathway
and MAPK pathway, the assessment of BRAF and KRAS mutational status as molecular bio-
marker for the survival benefit associated with the use of aspirin could be a next step to unravel
the biological effect of aspirin in colon cancer [17].
Therefore, the aim of this study was to investigate the association of low-dose aspirin use
after colon cancer diagnosis and survival of patients according to BRAF and KRAS mutation
status.
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Data on low dose aspirin use (80–100 mg), derived from the PHARMO Database Network
(PHARMO, Netherlands), were linked to the Eindhoven Cancer Registry (ECR). The validity
of the linkage of these cohorts was described previously [18]. The ECR serves about 1.5 million
inhabitants in the southern region of the Netherlands and is part of the nationwide Compre-
hensive Cancer Organisation (IKNL). The PHARMO Database Network is a population-based
network and combines data from different healthcare settings in the Netherlands. The Outpa-
tient Pharmacy Database was used for this study, which comprises drug dispensing records
from all community pharmacies. The records in this database contain information on the type
of product, date prescribed, dose and regimen, quantity, and route of administration. Drugs
are coded using the Anatomical Therapeutic Chemical classification [19]. The Comprehensive
Cancer Organisation is obliged to work according to the law on data protection; informed con-
sent of the patients for this specific study was not applicable.
As previously published, aspirin initiated or continued after diagnosis was associated with
improved survival for patients with colon cancer, but not for patients with rectal cancer, in our
cohort [20]. Therefore, only patients with colon cancer were included in this study.
The vital status of patients (alive/dead) was established from medical records or through
linkage of cancer registry data with the municipal population registries. As information on
hospital dispensing was not available, follow-up started 14 days after diagnosis of colorectal
cancer (T0), and was continued until last contact date (January 2012), date of loss to follow-up,
or date of death—whichever occurred first.
Patients who only used aspirin before diagnosis were also excluded (n = 40, see Fig 1). Non-
users were classified as those who never had a dispensing for aspirin or had a dispensing for
less than 14 days after diagnosis of colon cancer. Users were defined as those who had been
given a dispensing of aspirin for 14 days or more after a colon cancer diagnosis. The median
duration of one dispensing was 30 days and the mean dispensing number was 12 (range
1–220).
BRAF and KRAS tumor mutation analyses
The ECR-PHARMO cohort, as previously published by Bastiaannet et al, contained 3,586
patients [20]. Of this cohort, Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissues were
retrieved of 1,026 colon cancer patients who underwent a surgical resection between 2002 and
2008 [21]. Twenty-seven patients with more than one colon tumor at the time of diagnosis
were excluded from this cohort (Fig 1). Additionally, 63 patients were excluded because they
used aspirin before diagnosis or with a follow up less than 14 days. Of these patients, 599
patients were randomly selected with a ratio 1:2 for aspirin user: non-user, as was previously
described [22].
No significant demographic differences were calculated between the total cohort (n = 999)
and the randomly selected patients (n = 599) [22].
Of the included patients (n = 599), tumor areas on hematoxylin and eosin (H&E) stained
tumor sections were marked by an experienced pathologist/researcher. Guided by the H&E-
stained slides, 1–2 punches with a diameter of 2.0 mm diameter and variable length were taken
from the tumor focus, followed by DNA extraction as described by de Jong et al [21]. For
determination of KRAS and BRAFmutations status, hydrolysis probes assays were performed
for the major known mutations (hotspots) in codon 600 for BRAF, c.1799T>A; p.V600E and
codon 12 and 13 for KRAS; c.34G>A; p.G12S, c.34G>C; p.G12R, c.34G>T; p.G12C,
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c.35G>A; p.G12D, c.35G>C; p.G12A, c.35G>T; p.G12V, c.38G>A; p.G13D and c.37G>T; p.
G13C, as previously described [21]. Hydrolysis probe assays were analyzed using qPCR analy-
sis software (CFX manager version 3/0, Bio-Rad). Mutation detection was performed by two
independent observers (M.R. and R.E.). All primers used for the assays were previously
described [23].
Statistics
Statistical analyses were performed using the statistical packages SPSS (version 20.0 for Win-
dows, IBM SPSS statistics) and Stata (version 12 for windows, StataCorp LP). Statistical tests
were two-sided and considered significant at a p-value below 0.05.
A parametric survival model with an exponential (Poisson) distribution was used, with the
use of aspirin as time varying covariate. This method prevents the introduction of time-related
biases [24]. Non-users were defined from T0 until date of death or end of follow-up. Patients
were considered aspirin users from the moment of first prescription, mimicking an intention-
to-treat analysis. In order to investigate differential associations of aspirin use with overall
Fig 1. Flowchart of patients selected for analysis.
doi:10.1371/journal.pone.0170775.g001
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survival by tumor molecular subtype, stratified analyses were performed for BRAFwild-type /
BRAFmutation and KRAS wild-type / KRAS mutation, followed by an interaction analysis.
The interaction analysis was performed by including a cross product of BRAFmutation status
in the survival analysis and the use of aspirin and significance was assessed with the Wald test.
Adjustments for potential confounders were made for sex, age (groups), stage (pathological
stage and clinical stage if pathological stage was unknown), adjuvant chemotherapy (yes/no),
co-morbidity (yes/no) and tumor grade.
Survival curves were calculated according to the Simon-Makuch method, an alternative for
Kaplan Meier, with the ability to include time-varying covariates [25].
A subgroup analysis was performed by excluding patients with stage IV disease.
Results
Fig 1 shows the flowchart of the study population eligible for analysis. In this cohort, 29.9%
(179/599) of the patients were defined as aspirin users. Of the 179 patients who used aspirin
after diagnosis, 27 patients started using aspirin after diagnosis and 155 used already aspirin at
diagnosis. In total, 267 deaths were recorded before January 2012.
DNA was extracted from FFPE tumor tissues and BRAFmutation status (wild-type/muta-
tion) was successfully established in 98% of the samples. A BRAFmutation was found in 17%
(102/599) and a KRAS mutation was observed in 35% of colon tumors (212/599), in accor-
dance with previous studies [11–13, 26, 27].
Table 1 summarizes the clinical characteristics of the patients included in the analysis. Both
age and frequency of comorbidities were found to be higher in the group of aspirin users com-
pared to non-users. Lower disease stage and male sex were more often observed in aspirin
users compared to non-users.
Table 1. Baseline Characteristics of the cohort.
All patients Non-users Aspirin users
n % n % n %
Total 599 100 420 100 179 100
Sex Male 327 54.6 215 51.2 112 62.6
Female 272 45.4 205 48.8 67 37.4
Age category <65 189 31.6 158 37.6 31 17.3
66–74 189 31.6 118 28.1 71 39.7
75 and older 221 36.9 144 34.3 77 43.0
Year of diagnose 2002–2004 300 50.1 208 49.5 92 51.4
2005–2007 299 49.9 212 50.5 87 48.6
Disease stage I 95 15.9 57 13.6 38 21.2
II 237 39.7 166 39.7 71 39.7
III 176 29.5 121 28.9 55 30.7
IV 89 14.9 74 17.7 15 8.4
Comorbidity No 209 34.9 176 41.9 33 18.4
Yes 342 57.1 202 48.1 140 78.2
Missing 48 8 42 10 6 3.4
BRAF mutation analysis Wild-type 497 83 347 82.6 150 83.8
Mutation 102 17 73 17.4 29 16.2
KRAS mutation analysis Wild-type 387 64.6 274 65.2 113 63.1
Mutation 212 35.4 146 34.8 66 36.9
doi:10.1371/journal.pone.0170775.t001
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More detailed patient characteristics according to aspirin use and BRAF and KRAS muta-
tion status are shown in S1 Table. Aspirin use was equally distributed: 29% in patients with
wild-type BRAF tumors, 27% in patients with mutated BRAF tumors, and 29% in patients with
KRAS wild-type and 31% in patients with mutated KRAS tumors.
As shown in Table 2 and Fig 2 aspirin use after diagnosis was associated with an improved
overall survival in the total cohort (n = 599) (crude Rate Ratio (RR) 0.73, 95% Confidence
Interval (CI) 0.56–0.97, adjusted RR 0.64 (95% CI 0.48–0.86)). Fig 3 shows the survival curves
for these patients.
For patients with a BRAFwild-type tumor, aspirin use after diagnosis showed a RR for over-
all survival of 0.74 (95% CI 0.54–1.00), and when adjusted for potential confounders this effect
was more pronounced with an adjusted RR of 0.60 (95% CI 0.44–0.83, p = 0.002, Fig 3). For
patients with BRAFmutated tumors, aspirin use after diagnosis was not associated with an
improved survival (adjusted RR 0.74, 95% CI 0.39–1.38, p = 0.34). The Wald test showed a P
for interaction of 0.99, which suggests that the difference found between the group of patients
with a BRAFwild-type or mutation is based on chance.
For patients with a KRASmutated tumor and patients with a KRASwild-type tumor, aspirin
use after diagnosis was associated with an improved overall survival in the multivariate analysis
(KRAS wild-type RR 0.68 (0.67 95%CI 0.47–0.97) and KRAS mutant RR 0.56 (95% CI 0.34–
0.93)), (Table 2, Fig 3).
The results from the subgroup analysis that excluded patients with stage IV can be found in
S2 Table.
Table 2. Rate Ratio for Death (Time-Dependent Analysis Overall Survival), According to Tumor BRAF and KRAS mutation status, and use or no
use of Aspirin after Diagnosis.
n Events Univariate Multivariate
RR (95%CI) P-value RRa (95%CI) P-value
Overall 599
No aspirin use 420 199 1.00 (reference) 0.03 1.00 (reference) 0.003
Aspirin use 179 68 0.73 (0.56–0.97) 0.64 (0.48–0.86)
BRAF mutation status
Wild-type 497
No aspirin use 347 159 1.00 (reference) 0.05 1.00 (reference) 0.002
Aspirin use 150 55 0.74 (0.54–1.00) b 0.60 (0.44–0.83)
Mutation 102
No aspirin use 73 40 1.00 (reference) 0.34 1.00 (reference) 0.77
Aspirin use 29 13 0.74 (0.39–1.38) b 1.11 (0.57–2.16)
KRAS mutation status
Wild-type 387
No aspirin use 274 130 1.00 (reference) 0.11 1.00 (reference) 0.03
Aspirin use 113 43 0.75 (0.53–1.06) 0.67 (0.47–0.97)
Mutation 212
No aspirin use 146 69 1.00 (reference) 0.14 1.00 (reference) 0.03
Aspirin use 66 25 0.71 (0.45–1.11) 0.56 (0.34–0.93)
Significant values are printed in bold
a Adjusted for age, comorbidity, grade, stage and chemotherapy
b P-value for interaction = 0.99
doi:10.1371/journal.pone.0170775.t002
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Fig 2. Overall survival analysis for patients using aspirin versus patients not using aspirin, grouped
according to mutation status. * Test for interaction not significant.
doi:10.1371/journal.pone.0170775.g002
Fig 3. Survival curves for aspirin users versus non-users according to the Simon-Makuch method.
doi:10.1371/journal.pone.0170775.g003
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Discussion
Overview of findings
Increasing attention is paid to a personalized treatment approach, by stratifying patients into
subgroups based on biomarkers. This study investigated whether the survival benefit observed
in patients with colon cancer using aspirin could be associated with BRAF or KRAS mutational
status. This study found that BRAFmutation status and KRAS mutation status were not dis-
tinctive in the association between low-dose aspirin use and a survival benefit in patients with
colon cancer. In the multivariate analysis, patients with wild-type BRAF tumors, aspirin use
after diagnosis was associated with a significantly better outcome. However, the crude hazard
ratios in both groups (BRAFwild-type and mutation) are equal and the P-value for interaction
was non-significant. Because no statistical interaction was observed, the distinctiveness of
BRAFmutational status on the association between aspirin use and survival in the multivariate
analysis could very well be based on chance. Therefore, it could not be concluded from this
study that patients with BRAFmutated tumors should be withheld from using aspirin. The
subgroup analysis in patients with stage I-III colon cancer showed a reduced effect size. How-
ever, due to limitations in power, no firm conclusions can be drawn from the results of this
subgroup analysis.
Comparison with other studies
Nishihara et al [26] previously studied the effect of BRAFmutational status on colorectal can-
cer incidence and survival in patients using aspirin. BRAFmutational status showed to be of
influence on the incidence of colorectal cancer. BRAFwild-type was associated with a lower
risk of colorectal cancer, multivariable hazard ratio; 0.73 (95% CI 0.64–0.83) whereas BRAF
mutated tumors did not show a reduced risk of colorectal cancer (HR 1.03, 95% CI 0.76–1.38).
A survival analysis in this study was performed as an exploratory analysis, and in both sub-
groups (BRAFmutation and wild-type tumors) no association between the use of aspirin and
improved survival was found, in line with our study.
Strengths and limitations
Our study has several strengths. To the best of our knowledge, no studies have assessed the
association between KRAS, aspirin and survival in patients with (colon) cancer. Information
regarding aspirin use and dose was derived from prescriptions rather than patient recall,
resulting in a precise definition of regular aspirin use. By using a time-varying covariate for the
use of aspirin, the risk of non-differential misclassification is reduced [24]. Lastly, a robust and
reliable method was used to determine BRAF and KRAS mutational status, resulting in a 98%
successful determination of mutational status and therefore a relatively large cohort.
However, several limitations must be acknowledged. First, over-the-counter aspirin use
and adherence was unknown and could be a potential source of bias. Nevertheless, it has been
shown that pharmacy data can give valid estimates, despite over-the-counter availability of
aspirin [28]. It seems unlikely that a large fraction of patients bought aspirin over-the-counter:
low-dose aspirin is only indicated for secondary cardiovascular prevention in the Netherlands
and therefore this should always be made available through a doctor’s prescription. The main
reason for over-the-counter purchase of aspirin is its use as analgesic, however low-dose aspi-
rin does not suffice as analgesic. Moreover, the possible benefits of aspirin as treatment for
cancer were not widely known during the analysis period.
Second, this is a retrospective study in which patients were not randomized. Even after
adjustment for potential confounders, residual confounding may still be present. Confounding
Aspirin, BRAF and KRAS Mutation Status and Cancer Survival
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by indication could, in general, have resulted in overestimation of the results. For cancer
patients to be prescribed aspirin, patients should have a cancer prognosis which outweighs the
risk of cardiovascular disease. Patients to whom this does not apply should, in theory, not be
prescribed aspirin. These patients are then assigned into the non-user group which could have
resulted in an overestimation of the association between aspirin use and survival. The variation
in length of use of aspirin and the moment patients start using aspirin makes it difficult to con-
clude any causality from this study, only associations were observed. Therefore, the current
ongoing randomised controlled trials are highly warranted. However, this is a limitation of all
retrospective studies.
Third, no information regarding disease-specific survival was available in this study. How-
ever, a large meta-analysis of individual patient data found that the benefit of patients using
aspirin as secondary prevention for cardiovascular disease is only 0.91 (95% CI 0.82–1.00)
[29]. This can therefore not fully explain the observed overall survival benefit for the aspirin
users in the current study.
To the best of our knowledge, this study is one of the largest cohorts analyzing the associa-
tion between the use of aspirin, overall survival in colon cancer patients and mutational status
of BRAF and KRAS, however numbers were too small for any additional subgroup analyses.
Clinical implications
Precision medicine has gained more attention over the last couple of years and multiple
publications were dedicated to the discovery and development of clinical prognostic and
predictive biomarkers [11]. Nevertheless, conflicting results have been observed for every
previous appointed biomarker regarding the association between aspirin use and survival.
Proposed biomarkers associated with aspirin use and survival are COX-2, HLA class I,
PIK3CA mutation status and several specific genetic profiles [22, 30–32]. Mutations in
BRAF and KRAS, acting in the RAS-RAF-MAPK kinase cascade and mutated PIK3CA, acting
in PI3K-PTEN-AKT signaling pathway, are known for their contribution to the development
of CRC and are associated with cancer prognosis [11, 33]. The strong survival benefit in
patients with a PIK3CA mutation can only partly explain the effect of aspirin found in the
general cancer population. The magnitude of the clinical benefit as found in CRC cohorts,
cannot be explained by patients with a PIK3CA mutation solely, because of the low mutation
frequency (15%). Therefore, additional biological processes must be responsible for the
effect of aspirin on survival.
In this study we were focusing on the RAS-RAF-MAPK cascade, known for the crosstalk
with the PIK3CA pathway, in relation to aspirin use [17]. No differentiating effect of aspirin
use in BRAF or KRAS mutated tumors could be detected. It could be (cautiously) concluded
that biomarkers from the RAS-RAF-MAPK cascade and an activated PI3K-PTEN-AKT signal-
ing pathway may not be able to fully unravel the complexity and versatility of the aspirin effect
on cancer. Therefore, the evidence points more towards a generalized, systemic effect [5, 34].
One suggested hypothesis is the role of aspirin as thrombocyte aggregation inhibitor [34].
By inhibiting the aggregation of thrombocytes, which naturally shape around circulating
tumor cells, the immune system is able to detect and subsequently clear tumor cells from the
circulation. Another hypothesis could be found in the anti-inflammatory effects of aspirin
[35]. In the past years, several publications focused on the identification of subtypes of colorec-
tal cancer, highlighting the heterogeneity of the disease and aiming to improve optimal alloca-
tion of treatment modalities [11, 36, 37]. Linnekamp et al advocate that the development of
new agents should take place in a disease sub-type-specific fashion and in that manner gener-
ate more effective therapies [36]. These subtypes could also be the key to personalized
Aspirin, BRAF and KRAS Mutation Status and Cancer Survival
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treatment with aspirin. With this information and growing consensus on these subtypes, new
research could focus on the effect of aspirin in (inflammatory) specific subtypes.
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